SCHEMBL3210853

SCHEMBL3210853

Cc1nc(C(F)(F)F)cc(Br)c1O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NQO2 P16083 1/20 0.44
HSP90AA1 P07900 1/20 0.40
HSP90AB1 P08238 1/20 0.40
MEN1 O00255 1/20 0.37
CCR6 P51684 1/20 0.37
KMT2A Q03164 1/20 0.37
PTPN1 P18031 1/20 0.37
CYP3A4 P08684 3/20 0.36
TSHR P16473 3/20 0.36
ALDH1A1 P00352 2/20 0.36
HPGD P15428 2/20 0.36
TDP1 Q9NUW8 2/20 0.36
ALOX15 P16050 1/20 0.36
ALOX12 P18054 1/20 0.36
CASP1 P29466 1/20 0.36
RECQL P46063 1/20 0.36
HIF1A Q16665 1/20 0.36
HSD17B10 Q99714 1/20 0.36
NT5E P21589 1/20 0.34
KDM4E B2RXH2 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11985892 0.80 HSP90AA1 (0.47) HSP90AA1HSP90AB1MEN1KMT2ACYP3A4
SCHEMBL30054247 0.77 HSP90AA1 (0.48) HSP90AA1HSP90AB1KMT2AALDH1A1HPGD
SCHEMBL19711936 0.77 HSP90AA1 (0.48) HSP90AA1HSP90AB1KMT2AALDH1A1HPGD
SCHEMBL3208142 0.74 SMPD3 (0.41) HSP90AA1HSP90AB1MEN1KMT2ACYP3A4
SCHEMBL19712045 0.74 HPGD (0.38) HSP90AA1HSP90AB1MEN1KMT2ACYP3A4
SCHEMBL29987998 0.73 NQO2 (0.52) NQO2HSP90AA1MEN1KMT2ACYP3A4
SCHEMBL3210739 0.73 NQO2 (0.52) NQO2HSP90AA1MEN1KMT2ACYP3A4
SCHEMBL23885402 0.71 SMN1; SMN2 (0.37) L3MBTL1LMNAGAACYP2C19POLB
SCHEMBL30254535 0.71 SMN1; SMN2 (0.37) L3MBTL1LMNAGAACYP2C19POLB
SCHEMBL17119432 0.69 KDM4E (0.41) HSP90AA1HSP90AB1ALDH1A1NT5EKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240150362-A1 Substituted Pyrrolotriazines MOLECURE S.A. (PL) 2024-05-09 US disclosed
WO-2024042494-A1 SUBSTITUTED PYRROLOTRIAZINES MOLECURE SA (PL) 2024-02-29 WO disclosed
WO-2024042494-A1 SUBSTITUTED PYRROLOTRIAZINES MOLECURE SA (PL) 2024-02-29 WO disclosed
US-20100056515-A1 BENZIMIDAZOLE COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-03-04 US disclosed
EP-2088861-A2 BENZIMIDAZOLE COMPOUNDS Takeda Pharmaceutical Company Limited (JP) 2009-08-19 EP disclosed
WO-2008051533-A2 BENZIMIDAZOLE COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-05-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100056515-A1 BENZIMIDAZOLE COMPOUNDS HRH4, SSTR5, CNR1 NQO2 1350/4885HSP90AA1 3969/4885HSP90AB1 3413/4885
US-20240150362-A1 Substituted Pyrrolotriazines USP7, UBA7, USP5 NQO2 1207/4885HSP90AA1 1690/4885HSP90AB1 1702/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.